Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1953 2
1954 1
1956 1
1957 2
1958 1
1960 1
1961 1
1962 1
1966 1
1989 1
1993 1
1994 111
1995 234
1996 278
1997 268
1998 267
1999 265
2000 333
2001 318
2002 382
2003 343
2004 345
2005 322
2006 414
2007 393
2008 402
2009 442
2010 480
2011 536
2012 631
2013 713
2014 720
2015 778
2016 759
2017 728
2018 732
2019 556
2020 56
Text availability
Article attribute
Article type
Publication date

Search Results

10,480 results
Results by year
Filters applied: . Clear all
Page 1
International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma.
Kumar S, Paiva B, Anderson KC, Durie B, Landgren O, Moreau P, Munshi N, Lonial S, Bladé J, Mateos MV, Dimopoulos M, Kastritis E, Boccadoro M, Orlowski R, Goldschmidt H, Spencer A, Hou J, Chng WJ, Usmani SZ, Zamagni E, Shimizu K, Jagannath S, Johnsen HE, Terpos E, Reiman A, Kyle RA, Sonneveld P, Richardson PG, McCarthy P, Ludwig H, Chen W, Cavo M, Harousseau JL, Lentzsch S, Hillengass J, Palumbo A, Orfao A, Rajkumar SV, Miguel JS, Avet-Loiseau H. Kumar S, et al. Lancet Oncol. 2016 Aug;17(8):e328-e346. doi: 10.1016/S1470-2045(16)30206-6. Lancet Oncol. 2016. PMID: 27511158 Review.
Minimal residual disease in chronic lymphocytic leukaemia.
García Vela JA, García Marco JA. García Vela JA, et al. Med Clin (Barc). 2018 Feb 23;150(4):144-149. doi: 10.1016/j.medcli.2017.06.067. Epub 2017 Aug 31. Med Clin (Barc). 2018. PMID: 28864095 Review. English, Spanish.
iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL.
Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, Döhner H, Hillmen P, Keating M, Montserrat E, Chiorazzi N, Stilgenbauer S, Rai KR, Byrd JC, Eichhorst B, O'Brien S, Robak T, Seymour JF, Kipps TJ. Hallek M, et al. Blood. 2018 Jun 21;131(25):2745-2760. doi: 10.1182/blood-2017-09-806398. Epub 2018 Mar 14. Blood. 2018. PMID: 29540348
Biological and clinical consequences of NPM1 mutations in AML.
Heath EM, Chan SM, Minden MD, Murphy T, Shlush LI, Schimmer AD. Heath EM, et al. Leukemia. 2017 Apr;31(4):798-807. doi: 10.1038/leu.2017.30. Epub 2017 Jan 23. Leukemia. 2017. PMID: 28111462 Review.
Multiple Myeloma Minimal Residual Disease.
Paiva B, García-Sanz R, San Miguel JF. Paiva B, et al. Cancer Treat Res. 2016;169:103-122. doi: 10.1007/978-3-319-40320-5_7. Cancer Treat Res. 2016. PMID: 27696260 Review.
Targeting minimal residual disease: a path to cure?
Luskin MR, Murakami MA, Manalis SR, Weinstock DM. Luskin MR, et al. Nat Rev Cancer. 2018 Apr;18(4):255-263. doi: 10.1038/nrc.2017.125. Epub 2018 Jan 29. Nat Rev Cancer. 2018. PMID: 29376520 Free PMC article. Review.
Methods of Detection of Measurable Residual Disease in AML.
Zhou Y, Wood BL. Zhou Y, et al. Curr Hematol Malig Rep. 2017 Dec;12(6):557-567. doi: 10.1007/s11899-017-0419-5. Curr Hematol Malig Rep. 2017. PMID: 29098609 Review.
10,480 results
Jump to page
Feedback